{"entity":{"id":"fate-therapeutics","kind":"company","name":"Fate Therapeutics","aka":[],"tldr":"Fate Therapeutics builds iPSC-derived off-the-shelf CAR-T and CAR-NK cells (FT819, FT522) for cancer and autoimmune disease.","summary":"Fate Therapeutics, based in San Diego and listed as FATE, builds off-the-shelf CAR-T and CAR-NK cells derived from induced pluripotent stem cells, including FT819 and FT522, for cancer and autoimmune disease. FT819 is a clonal iPSC-derived CD19 CAR-T, FT522 is a CD19 CAR-NK with alloimmune defence receptors designed to avoid conditioning chemotherapy, the company presented at ASCO and EULAR 2026, and it has a solid-tumour collaboration with Ono. OnCo links it to diffuse large B-cell lymphoma, to allogeneic cell therapy, CAR-NK and CAR-T, to CD19 as a target and to ideas on qualifying one iPSC master cell bank for many products. Manufacturing cost and time for living medicines is the bottleneck iPSC-derived cells are meant to relieve. Whether iPSC-derived cells persist and perform as well as patient-derived ones is the open question.","asOf":"2026-09-04","links":[{"label":"ASCO/EULAR 2026","url":"https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-announces-presentations-2026-asco-and-eular"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-nk-macrophage","car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"cell-therapy","website":"https://fatetherapeutics.com","ticker":"FATE","investors":[],"funding":[]},"route":"/companies/fate-therapeutics/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/"},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"idea":[{"id":"idea-bio2-nk-cells-for-mrd","kind":"idea","name":"Off-the-shelf natural killer cells to sweep up residual disease","route":"/ideas/idea-bio2-nk-cells-for-mrd/"},{"id":"idea-reg-ipsc-master-bank-qualified-once","kind":"idea","name":"Qualify one iPSC master cell bank once for many off-the-shelf cell products","route":"/ideas/idea-reg-ipsc-master-bank-qualified-once/"}],"institution":[{"id":"minnesota-masonic","kind":"institution","name":"Masonic Cancer Center, University of Minnesota","route":"/institutions/minnesota-masonic/"}]}}